Amplifon secures €1.35 billion loan for GN Hearing deal, shares stay in focus on Milan
23.06.2026 - 19:49:26 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 19:43.
Amplifon (IT0004056880) has arranged a €1.35 billion senior loan to finance its purchase of GN Hearing, a move that underlines the Italian group’s expansion push in the global audiology market as reported by Alliance News via MarketScreener. MarketScreener coverage of the loan agreement The transaction keeps Amplifon shares in focus on Borsa Italiana, where the company is part of the FTSE MIB benchmark.
Details of the GN Hearing financing
According to the Alliance News report, Amplifon has signed a €1.35 billion senior loan facility with a maximum tenor of 24 months to support the GN Hearing acquisition, providing bridge-style funding for the deal timeline. Alliance News note on the senior loan The acquisition of GN Hearing, announced earlier in 2026, is expected to close by the end of 2026 subject to customary regulatory approvals and other closing conditions, which would significantly expand Amplifon’s footprint in hearing aids and related services.
The same report indicates that Amplifon shares recently traded around €9.95 to €10.18 on Milan, a muted move that suggests investors are now weighing the additional leverage against the strategic benefits of integrating GN Hearing. MarketScreener price and consensus page for Amplifon GN Hearing is currently part of Denmark’s GN Group, which is listed on Nasdaq Copenhagen alongside sector peers such as Demant, underscoring the cross-European dimension of this transaction in the hearing care space.
What analysts and the market indicate
Consensus compiled by MarketScreener shows an average analyst price target of about €12.8 for Amplifon, compared with a last close near €9.98, implying upside expectations among covering banks and brokers even as the company takes on new debt for GN Hearing. Analyst consensus overview on MarketScreener Several international houses such as Goldman Sachs, JPMorgan and UBS follow the wider European medical technology and hearing care sector, where Amplifon competes with players like Demant and Sonova that are listed in indices such as OMXC25 and SMI.
Market data from Borsa Italiana show a market capitalization for Amplifon in the mid single-digit billion euro range, positioning the company among the larger specialized consumer health names on the Milan exchange. Borsa Italiana profile and price data for Amplifon In trading on 2026-06-23 at around 17:30 local time, Amplifon shares on Borsa Italiana were quoted close to €10 per share, broadly in line with the levels reported in international market commentary.
All news and data on the Amplifon shares
Track recent updates on Amplifon, including the GN Hearing acquisition financing, analyst estimates and price data for the Milan-listed shares.
How Amplifon earns its money
Amplifon generates revenue primarily through the sale and fitting of hearing aids and related services, operating a large global network of specialized stores and clinics under brands such as Amplifon, Miracle-Ear and Beter Horen. The company offers diagnostic assessments, personalized fitting, aftercare and accessories, placing it in direct competition with groups like Sonova and Demant in the international hearing care industry.
Where the shares trade today
The Amplifon shares (IT0004056880) trade on 2026-06-23 at 17:30 on Borsa Italiana at 9.98 euros.
Key data on the Amplifon shares
- Company: Amplifon S.p.A.
- ISIN: IT0004056880
- WKN: A2AD0K
- Ticker: AMP
- Trading venue: Borsa Italiana
- Price (as of 2026-06-23, 17:30): 9.98 EUR
- Market cap: 4.5 billion EUR (as of 2026-06-23)
- Sector / industry: Healthcare - Hearing care services and medical devices
- Index membership: FTSE MIB
- Next earnings date: 2026-07-30
This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. All data are based on sources believed to be reliable but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.
